Target
$48.62 → $48.63
Current stock research snapshot · 7/8/26 49 days old
QGENQIAGEN
Investment conviction●●○○○2 of 5 · current snapshot
Research target$48.63Current stock price target
Investment thesis statusNEEDS_MORE_DATALast reviewed 7/8/26
Market cap$8.27BSnapshot value · 7/8/26
Research history
See all QGEN changes ↗What changed
Sample prep + PCR + NGS library prep + bioinformatics. Straddles Measure and Read. Installed base of sample-prep instruments drives recurring kit revenue.
NGS sample-prep volume growth (every sequencer needs prep); QIAstat-Dx syndromic testing; bioinformatics recurring revenue.
Competitive pressure from Thermo/Illumina in sample prep; academic budget sensitivity; slower growth in mature PCR market.
Bullish — Two potential buyers begin formal due diligence in sales process (CTFN/Bloomberg reports, Aug 25). [X search Aug 2026]
Snapshot · 7/8/26🟢 Lean-Bull · 13F 17+/7-×0.5 · short↑0.18
Snapshot · 7/8/26Timestamped research update
Deep research update
496 words · Updated Aug 2, 2026 · 5 sources
Research in development: this latest 496-word update is published for context while it is expanded toward the 1,000-word editorial standard.
QIAGEN provides "Sample to Insight" solutions — sample preparation (nucleic acid extraction/purification kits, automation), molecular diagnostics (QuantiFERON TB testing, QIAstat syndromic panels, QIAcuity digital PCR), and bioinformatics software. The consumables-heavy model drives ~70%+ recurring revenue from lab workflows that depend on QIAGEN's validated extraction chemistry.
FY2025 net sales were $2.09B (+6% actual, +5% CER), at the high end of 4-5% CER guidance. Growth pillars (sample technologies, QuantiFERON, NGS, digital PCR, syndromic testing) delivered $1.49B CER (+8% CER). Adjusted operating income margin was 29.5% (+80 bps YoY). FY2026 guidance: ≥5% CER sales growth, growth pillars → $1.64B CER (+9% CER), adjusted EPS ≥$2.50 CER.
Sample prep is the front door to ALL molecular diagnostics — the picks-and-shovels of the Healthspan "Measure" layer. As diagnostics shift from phenotypic to molecular (liquid biopsy, NGS panels, proteomics), every additional test type adds a sample prep step. QIAGEN captures this as recurring consumables revenue on an instrument base that has high switching costs.
- FY2025 $2.09B revenue with 29.5% adj operating margin — consumables-heavy model driving profitability at scale
- Growth pillars delivered $1.49B at +8% CER — accelerating above company average, confirming NGS/sample prep tailwinds
- FY2026 guidance: growth pillars expected to reach ~$1.64B CER at +9% CER — management sees acceleration
- Sample prep market was ~$9.64B in 2025, projected $13.64B by 2030 (CAGR ~7.2%) — QIAGEN is share leader in extraction/purification
- Consumables hold ~55.2% share of total sample prep market — QIAGEN's core revenue type benefits disproportionately from market growth
- QIAcuity digital PCR expansion + NVIDIA AI collaboration (graph-based drug discovery) = positioning for next-gen workflows
- New sample prep instruments announced for 2025-2026 launch cycle — refreshes instrument base, drives next wave of consumable lock-in
Protocol lock-in. A lab that has validated QIAGEN's QIAamp chemistry into its CLIA/CAP-certified NGS workflow faces 6-18 months of re-validation to switch. The cost of re-validation typically exceeds any per-kit savings from a competitor. This is a true economic moat — not protectionist, but workflow-integrated. The barriers are: (a) regulatory re-validation cost, (b) lab staff retraining, (c) cross-comparability risk with historical patient data, (d) instrument/chemistry compatibility matrix.
- Thermo Fisher (KingFisher, MagMAX) and Illumina (library prep kits) compete directly — QIAGEN's share is large but not uncontested
- Research budget pressure from NIH/European funding cycles can slow instrument placements
- Q2 2026 earnings are imminent (early August) — unknown quarter could carry positive or negative surprise
- Currency headwind: ~30-40% of revenue is EUR-denominated; strong USD squeezes reported growth
- What is QIAGEN's exact sample prep market share vs Thermo Fisher and Promega?
- How much of the $1.49B growth pillar revenue is specifically sample prep vs QuantiFERON vs digital PCR?
- Can QIAcuity digital PCR displace enough qPCR volume to drive an instrument upgrade cycle?
INTACT — sample prep is a genuine bottleneck with protocol lock-in economics. QIAGEN's scale and installed base are durable advantages.
Primary and supporting material
Sources
5 sources preserved from the latest qualified research update.